Mustafa özgüroğlu
Mustafa özgüroğlu
Verified email at istanbul.edu.tr - Homepage
Title
Cited by
Cited by
Year
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ...
New England Journal of Medicine 377 (20), 1919-1929, 2017
19232017
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ...
New England Journal of Medicine 377 (4), 352-360, 2017
11362017
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ...
New England Journal of Medicine 379 (24), 2342-2350, 2018
11202018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ...
The Lancet 392 (10142), 123-133, 2018
4592018
Apalutamide for metastatic, castration-sensitive prostate cancer
KN Chi, N Agarwal, A Bjartell, BH Chung, AJ Pereira de Santana Gomes, ...
New England Journal of Medicine 381 (1), 13-24, 2019
3672019
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
3472019
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
F Barlesi, J Vansteenkiste, D Spigel, H Ishii, M Garassino, F de Marinis, ...
The Lancet Oncology 19 (11), 1468-1479, 2018
2122018
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a …
K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ...
The Lancet Oncology 20 (5), 686-700, 2019
1632019
Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC—update from PACIFIC
JE Gray, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ...
Journal of Thoracic Oncology 15 (2), 288-293, 2020
1272020
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
MD Galsky, JÁA Arija, A Bamias, ID Davis, M De Santis, E Kikuchi, ...
The Lancet 395 (10236), 1547-1557, 2020
882020
IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD …
D Spigel, F De Marinis, G Giaccone, N Reinmuth, A Vergnenegre, ...
Annals of Oncology 30, v915, 2019
812019
The role of US and MR imaging in detecting local chest wall tumor recurrence after mastectomy
MH Yilmaz, G Esen, Y Ayarcan, F Aydogan, M Özgüroglu, G Demir, ...
Diagnostic and Interventional Radiology 13 (1), 13, 2007
542007
KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open …
K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ...
Lancet 392 (10142), 123-133, 2018
522018
Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC
RS Herbst, G Giaccone, F de Marinis, N Reinmuth, A Vergnenegre, ...
New England Journal of Medicine 383 (14), 1328-1339, 2020
462020
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
R Hui, M Özgüroğlu, A Villegas, D Daniel, D Vicente, S Murakami, T Yokoi, ...
The Lancet Oncology 20 (12), 1670-1680, 2019
462019
Survival with olaparib in metastatic castration-resistant prostate cancer
M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 383 (24), 2345-2357, 2020
452020
IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo+ PBC in previously …
E Grande, M Galsky, JAA Arija, M De Santis, ID Davis, M Mencinger, ...
Annals of Oncology 30, v888-v889, 2019
392019
Metastatic cardiac myxoma
K Kaynak, K Beşirli, C Arslan, M Özgüroğlu, B Öz
The Annals of thoracic surgery 72 (2), 623-625, 2001
392001
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
K Kato, MA Shah, P Enzinger, J Bennouna, L Shen, A Adenis, JM Sun, ...
Future Oncology 15 (10), 1057-1066, 2019
382019
Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor–positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial
G Jerusalem, RH de Boer, S Hurvitz, DA Yardley, E Kovalenko, ...
JAMA oncology 4 (10), 1367-1374, 2018
382018
The system can't perform the operation now. Try again later.
Articles 1–20